10.3390/microorganisms11122882
13 In 1993, The Journal of Clinical Apheresis published a paper detailing the use of TPE as either a first- or second-line therapy to be used with other modalities on disorders such as Raynauds disease, systemic lupus erythematosus, coagulation factor inhibitors, familial hypercholesterolemia, acute Guillain-Barr syndrome, chronic inflammatory demyelinating polyneuropathy, myasthenia gravis, cryoglobulinemia, Goodpastures syndrome, and thrombotic thrombocytopenic purpura
Averaged LD cycle and total 24-h respiratory exchange ratio and energy expenditure were analysed per genotype and per sex
In contrast, GLP-1 QMP/LX was recycled equally well as GLP-1 QMP, about 4.5-fold more efficiently than GLP-1 WT (Fig
DT-109 ameliorates nonalcoholic steatohepatitis in nonhuman primates